S&P 500   4,191.98
DOW   33,426.63
QQQ   336.51
Mount Etna volcano erupts, raining ash on Catania, forcing flight suspension at local airport
Laser breakthrough could send stock soaring 2,467% (Ad)
China tells tech manufacturers to stop using Micron chips, stepping up feud with United States
Stock market today: Asian shares mostly rise despite worries about US debt talks
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
SpaceX launches two Saudi astronauts on private flight to space station
Civil rights groups warn tourists about Florida in wake of 'hostile' laws
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
South Korean, German leaders agree to cooperate on supply chains, North Korea
Animal rights activists protest octopus farm plans in Spain
S&P 500   4,191.98
DOW   33,426.63
QQQ   336.51
Mount Etna volcano erupts, raining ash on Catania, forcing flight suspension at local airport
Laser breakthrough could send stock soaring 2,467% (Ad)
China tells tech manufacturers to stop using Micron chips, stepping up feud with United States
Stock market today: Asian shares mostly rise despite worries about US debt talks
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
SpaceX launches two Saudi astronauts on private flight to space station
Civil rights groups warn tourists about Florida in wake of 'hostile' laws
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
South Korean, German leaders agree to cooperate on supply chains, North Korea
Animal rights activists protest octopus farm plans in Spain
S&P 500   4,191.98
DOW   33,426.63
QQQ   336.51
Mount Etna volcano erupts, raining ash on Catania, forcing flight suspension at local airport
Laser breakthrough could send stock soaring 2,467% (Ad)
China tells tech manufacturers to stop using Micron chips, stepping up feud with United States
Stock market today: Asian shares mostly rise despite worries about US debt talks
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
SpaceX launches two Saudi astronauts on private flight to space station
Civil rights groups warn tourists about Florida in wake of 'hostile' laws
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
South Korean, German leaders agree to cooperate on supply chains, North Korea
Animal rights activists protest octopus farm plans in Spain
S&P 500   4,191.98
DOW   33,426.63
QQQ   336.51
Mount Etna volcano erupts, raining ash on Catania, forcing flight suspension at local airport
Laser breakthrough could send stock soaring 2,467% (Ad)
China tells tech manufacturers to stop using Micron chips, stepping up feud with United States
Stock market today: Asian shares mostly rise despite worries about US debt talks
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
SpaceX launches two Saudi astronauts on private flight to space station
Civil rights groups warn tourists about Florida in wake of 'hostile' laws
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
South Korean, German leaders agree to cooperate on supply chains, North Korea
Animal rights activists protest octopus farm plans in Spain
NYSE:CTLT

Catalent (CTLT) Price Target & Analyst Ratings

$37.17
+5.03 (+15.65%)
(As of 05/19/2023 08:48 PM ET)
Compare
Today's Range
$33.78
$37.91
50-Day Range
$31.86
$71.20
52-Week Range
$31.45
$115.33
Volume
15.86 million shs
Average Volume
3.67 million shs
Market Capitalization
$6.69 billion
P/E Ratio
16.45
Dividend Yield
N/A
Price Target
$74.30

Catalent Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 11 Analyst Ratings

Consensus Analyst Price Target

$74.30
99.89% Upside
High Prediction$145.00
Average Prediction$74.30
Low Prediction$28.00
TypeCurrent
5/22/22 to 5/22/23
1 Month Ago
4/22/22 to 4/22/23
3 Months Ago
2/21/22 to 2/21/23
1 Year Ago
5/22/21 to 5/22/22
Consensus Rating
Hold
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
5 Buy rating(s)
6 Buy rating(s)
6 Buy rating(s)
Hold
6 Hold rating(s)
5 Hold rating(s)
3 Hold rating(s)
1 Hold rating(s)
Sell
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$74.30$88.50$96.30$142.86
Predicted Upside99.89% Upside36.66% Upside35.44% Upside19.19% Upside
Get Catalent Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CTLT and its competitors with MarketBeat's FREE daily newsletter.


CTLT Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CTLT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Catalent Stock vs. The Competition

TypeCatalentMedical CompaniesS&P 500
Consensus Rating Score
2.27
2.66
2.48
Consensus RatingHoldBuyHold
Predicted Upside99.89% Upside736.80% Upside29.67% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/21/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Neutral
5/21/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$40.00 ➝ $35.00-5.84%
5/15/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$55.00 ➝ $29.00-11.75%
5/8/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$58.00 ➝ $41.00+15.62%
5/8/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underperform$28.00-20.23%
4/17/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Neutral$82.00 ➝ $53.00+14.42%
4/14/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Smock
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
2/9/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$81.00 ➝ $85.00+19.20%
11/7/2022Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
11/2/2022KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$125.00 ➝ $85.00+71.61%
9/6/2022Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$145.00+63.53%
8/30/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$130.00 ➝ $110.00+19.20%
8/30/2022UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$145.00 ➝ $132.00+43.04%
(Data available from 5/22/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












CTLT Price Target - Frequently Asked Questions

What is Catalent's consensus rating and price target?

According to the issued ratings of 11 analysts in the last year, the consensus rating for Catalent stock is Hold based on the current 1 sell rating, 6 hold ratings and 4 buy ratings for CTLT. The average twelve-month price prediction for Catalent is $74.30 with a high price target of $145.00 and a low price target of $28.00. Learn more on CTLT's analyst rating history.

Do Wall Street analysts like Catalent more than its competitors?

Analysts like Catalent less than other Medical companies. The consensus rating for Catalent is Hold while the average consensus rating for medical companies is Buy. Learn more on how CTLT compares to other companies.

Is Catalent being upgraded or downgraded by Wall Street analysts?

Over the previous 90 days, Catalent's stock had 6 downgrades and 1 upgrade by analysts.

Does Catalent's stock price have much upside?

According to analysts, Catalent's stock has a predicted upside of 30.65% based on their 12-month price targets.

What analysts cover Catalent?

Stock Ratings Reports and Tools

This page (NYSE:CTLT) was last updated on 5/22/2023 by MarketBeat.com Staff

My Account -